| Document |
Document Title |
|
WO/2024/048528A1 |
The present invention provides a mechanosignaling inhibitor containing a substance capable of suppressing the expression or function of LSMEM2 as an active ingredient.
|
|
WO/2024/047214A1 |
The present invention provides Fusobacterium nucleatum, or a lysate thereof, or a culture supernatant thereof, for use in the prevention and/or treatment of a bacterial infection. The invention also provides a pharmaceutical composition ...
|
|
WO/2024/048687A1 |
The present invention provides a pharmaceutical composition that contains an MYT1 inhibitor as an active ingredient, that is for therapy or prevention of cancer in a patient exhibiting RB1 functional deterioration, and that is to be used...
|
|
WO/2024/050139A1 |
Embodiments include cardiac myosin inhibitors for laboratory and therapeutic use. Methods of preserving cardiac cells in media/buffer are described herein. Cardiac myosin inhibitors can also be used therapeutically to inhibit the modulat...
|
|
WO/2024/048792A1 |
The present disclosure provides a composition for treating viral infections. In one mode, the present disclosure provides a composition that is for treating viral infections in subjects, and that includes a nucleic acid construct having,...
|
|
WO/2024/048542A1 |
This medicament, which contains, together or separately in combination with a PARP inhibitor, an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, is useful for treating and/or preventing cancer.
|
|
WO/2024/049279A2 |
The present invention relates to sustained-release microspheres containing a high amount of leuprolide, an injectable preparation comprising same, and a preparation method therefor. During administration, leuprolide is released at a suff...
|
|
WO/2024/047811A1 |
Provided is a method for treating lymphoma. Use is made of a composition for treating lymphoma, the composition containing BCV, a pharmaceutically acceptable salt thereof, or a solvate of the BCV or the salt thereof. The lymphoma may b...
|
|
WO/2024/048782A1 |
The disclosure relates generally to methods of treating central nervous system disorders using (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane (i.e. centanafadine) or a pharmaceutically acceptable salt thereof. More particularly, t...
|
|
WO/2024/048750A1 |
[Problem] To provide novel eyedrops for inhibiting myopia progression that can easily inhibit the progression of myopia simply by dropping into the eye. [Solution] This problem is solved by α1 blocker-containing eyedrops for inhibiting ...
|
|
WO/2024/047394A1 |
The present disclosure relates generally to methods of treating T-cell lymphomas with combination therapies.
|
|
WO/2024/042554A1 |
The present invention relates to pharmaceutical composition comprising (i) a peroxisome proliferator-activated receptor (PPAR) activating fatty acid and/or a cathelicidin (LL37) compound, its precursors or analogue thereof; (ii) a vitami...
|
|
WO/2024/043257A1 |
This medicament is useful for treatment and/or prevention of a cancer, said medicament containing a RET kinase inhibitor and an antibody or fragment thereof together or separately, said antibody or fragment thereof having immunological r...
|
|
WO/2024/041172A1 |
To solve the problem that existing microneedles cannot achieve continuous and controllable adjustment of blood glucose and are prone to breakage to cause inflammation and infection in the skin, a microneedle for treating diabetes is prov...
|
|
WO/2024/043252A1 |
This pharmaceutical containing, collectively or separately as a combination, an antibody having immunological reactivity with respect to CAPRIN-1 protein or a fragment of said antibody, and an epidermal growth factor receptor (EGFR) inhi...
|
|
WO/2024/043258A1 |
This pharmaceutical product is useful for the treatment and/or prevention of cancer and contains the following components combined with each other in a blended or separated form: an antibody or a fragment thereof having immunological rea...
|
|
WO/2024/041083A1 |
The present invention belongs to the technical field of medicine, and particularly relates to an antifungal solution, a preparation method therefor, and use thereof. The present invention provides an antifungal solution. Raw materials fo...
|
|
WO/2024/042050A1 |
The present invention relates to a MEK inhibitor or a pharmaceutically acceptable salt, a metabolite or derivate thereof for use in a method for the treatment and/or prophylaxis of a coronavirus associated disease in a subject, wherein t...
|
|
WO/2024/043242A1 |
Provided is a drug for preventing or treating heart failure, that is effective and that does not have a blood pressure lowering effect. The present invention pertains to: a pharmaceutical composition for preventing or treating heart fa...
|
|
WO/2024/041535A1 |
The present disclosure relates to a nano-composition, a preparation method therefor, and use thereof. The nano-composition is formed by self-assembly of an oligopeptide containing a tryptophan dipeptide motif and cisplatin. The general f...
|
|
WO/2024/042160A1 |
The instant invention relates to the use of a substance with sodium-hydrogen antiporter 1 inhibitory activity (NHE1 inhibitor) as active ingredient in a therapeutic agent with sodium-hydrogen antiporter 1 inhibitory activity for the trea...
|
|
WO/2024/044548A1 |
Described herein are approved products and methods of using approved products for treating relapsed and refractory multiple myeloma in a patient. Also described herein are methods of selling or offering for sale an approved product.
|
|
WO/2023/045266A9 |
The use of FGFR and a related signaling pathway inhibitor thereof in the preparation of a drug for treating an FGFR2 mutant tumor. An FGF/FGFR2 signal drives formation of triple negative breast cancer and promotes an epithelial-to-mesenc...
|
|
WO/2024/044398A1 |
A composition is orally or topically administered to a patient susceptible to infection by an orthopoxvirus such as monkeypox (mpox). The composition includes inhibitors configured to bind to orthopoxvirus envelope proteins, e.g., MPXV A...
|
|
WO/2024/040242A1 |
This disclosure is directed to combinations comprising modulators of PDK1 represented by the following structural formula (I), and a second therapeutic agent or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, an...
|
|
WO/2024/037644A1 |
The present invention provides a polyethylene glycol (PEG)-modified glucocorticoid medicament and use thereof, including, but not limited to, asthma, chronic obstructive pulmonary disease, bronchitis, rhinitis, and the like, and relates ...
|
|
WO/2024/040175A1 |
The present disclosure relates to methods of treating cancer, such as lung cancer (e.g., non-small cell lung cancer) by administering a dry powder to the respiratory tract of a subject in need thereof (e.g., by oral inhalation), the dry ...
|
|
WO/2024/038440A1 |
The present invention provides a pharmaceutical composition including cannabigerol, and methods of using same, such as for increasing therapeutic efficacy of an immune checkpoint inhibitor, or for the treatment of cancer.
|
|
WO/2024/039183A1 |
The present invention relates to a composition for inhibiting angiogenesis, the composition comprising stepogenin as an active ingredient. The stepogenin according to the present invention may inhibit the proliferation and migration of v...
|
|
WO/2024/038002A1 |
The present invention relates to the prevention or mitigation of adverse effects related to gene therapy, such as the formation of anti-drug antibodies. Specifically, the invention relates to the prevention or mitigation of such side eff...
|
|
WO/2024/037498A1 |
The present invention relates to the field of pharmaceuticals, and specifically, to a combination therapy for treating ovarian cancer. It is discovered that the combination therapy of an FAK inhibitor and a chemotherapeutic can significa...
|
|
WO/2024/037521A1 |
The present invention relates to a combined treatment composition for tumor treatment and a combined treatment method. The combined treatment composition or a medicine box comprises a therapeutically effective amount of a platinum chemot...
|
|
WO/2024/039256A1 |
A method of treating Parkinson's disease in a patient who is receiving N doses of levodopa per day to provide a total daily dose of X mg of levodopa and who is starting to experience motor fluctuations or starting to show signs of "weari...
|
|
WO/2024/036274A1 |
The present disclosure provides pharmaceutical combinations comprising MetAP2 inhibitors for the treatment of interstitial lung disease, including pulmonary fibrosis.
|
|
WO/2024/033625A1 |
The present invention relates to a compound for use in a method of increasing trough lung function in a patient suffering from chronic obstructive pulmonary disease (COPD), wherein the compound is ensifentrine or a pharmaceutically accep...
|
|
WO/2024/036257A1 |
Provided herein are methods for treating drug addiction in a subject, the method comprising activating neurokinin B (NKB)-expressing neurons of the subject. Also provided herein are compositions useful for the treatment of drug addiction...
|
|
WO/2024/033513A1 |
The present invention relates to a quinazoline carboxamide azetidine compound, and to pharmaceutical combinations and compositions comprising such a compound preferably together with at least one distinct therapeutic agent, preferably an...
|
|
WO/2024/034652A1 |
The present disclosure provides: a tertiary amide derivative substituted by quaternary carbon that is useful as a medicine and a pharmaceutically acceptable salt of the tertiary amide derivative; a pharmaceutical composition comprising t...
|
|
WO/2024/035884A1 |
Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: • a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically ...
|
|
WO/2024/033537A1 |
There is provided herein a combination of compound of formula (I), which is a bifunctional compound with G12D mutant KRAS inhibitory activity, or a pharmaceutically acceptable salt thereof, and an anti-cancer agent for use in the treatme...
|
|
WO/2024/033627A1 |
The invention relates to a liquid pharmaceutical composition comprising a dose of a compound which is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the liquid pharmaceutical composition provides a blood plasma conce...
|
|
WO/2024/033280A1 |
The present invention relates to novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments as well as methods of their use and manufacture. Said compounds are particularly useful...
|
|
WO/2024/034580A1 |
The present invention provides a technology for detecting, with high sensitivity, a specific protein that can be used as a marker for cancer. More specifically, the present invention provides a method, etc. for detecting CEACAM1, the met...
|
|
WO/2024/033538A1 |
There is provided herein a combination of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and an anti-cancer agent for use in the treatment of cancer, wherein the compound of formula (I) and the anti-cancer agen...
|
|
WO/2024/033626A1 |
The present invention relates to a compound for use in a method for decreasing the frequency and/or severity of chronic obstructive pulmonary disease (COPD) exacerbations in a patient suffering from COPD, wherein the compound is ensifent...
|
|
WO/2024/034606A1 |
Provided are: a simple and highly accurate sample test method which can be applied to the evaluation of the presence or absence of at least one selected from the group consisting of a gynecological cancer and a precancerous lesion thereo...
|
|
WO/2024/033399A1 |
Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cells and evaluated Sig-1R implication in stromal cues integration by PCC from signaling transmission to biological outcomes, at the cellular and physiological le...
|
|
WO/2024/035864A1 |
The present disclosure relates to therapeutic agents and combinations thereof (e.g., pharmaceutical compositions) for the treatment of inflammation and an inflammatory disease or disorder in a subject, tissue or cell.
|
|
WO/2024/034685A1 |
The present invention provides a novel copolymer usable in drug delivery technology. The present invention relates to a drug conjugate in which a target-specific molecule is bound to a copolymer X comprising structural units represente...
|
|
WO/2024/028794A1 |
The disclosure provides for methods and compositions that target the interaction of αV/β1 integrin and monomeric MPO in ovarian cancer and other hyperproliferative disorders. Accordingly, aspects of the disclosure relate to a method fo...
|
